CD4 and inflammatory bowel disease: Importantly, similar transcriptomic shifts were observed in ex vivo-stimulated CD4+ T cells from patients with IBD, suggesting that subclinical immune dysregulation persists and could be amenable to therapeutic modulation using our approach.